Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
LEXINGTON, Massachusetts, August 3 /PRNewswire-FirstCall/ -- Shire plc
(LSE: SHP, NASDAQ: SHPGY ), the global specialty biopharmaceutical company,
today reported positive results from the first
of three Phase III studies of
velaglucerase alfa, its enzyme replacement therapy in development fo...
World's First Cardiac Adult Stem Cell Patient Receives Infusion
Trial taking place in Louisville, KY
LOUISVILLE, Ky., July 24 /PRNewswire-USNewswire/ -- Michael (Mike) Jones has become the world's first
recipient of adult cardiac stem cells to treat congestive heart failure. Jones' infusion on July 17 marks the world's first
Researchers Create First Targeted Knockout Rats Using Zinc Finger Nuclease Technology
MILWAUKEE, RICHMOND, Calif., ST LOUIS, PALO ALTO, Calif., and PARIS, July 23 /PRNewswire-FirstCall/ -- Scientists from The Medical College of Wisconsin in Milwaukee, Sangamo Biosciences, Inc., (Nasdaq: SGMO ), Sigma-Aldrich Corporation (Nasdaq: SIAL ), Open Monoclonal Technology...
Lilly and New York City Mayor Michael R. Bloomberg Announce Lilly Agrees to be First Tenant of East River Science Park; Issue Urgent Call for Healthcare Reform that Protects Innovation and Jobs
INDIANAPOLIS, July 22 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) announced today during a lease signing event that it has become the first
tenant of New York City's new Alexandria Center for Science and Technology at East River Science Park, a development that sh...
GNC Unveils Study Results for First and Only Nitric Oxide Product Clinically Proven to Improve Physical Performance at NSCA Conference in Las Vegas
LAS VEGAS, July 13 /PRNewswire-FirstCall/ -- GNC, the leading global specialty retailer of nutritional products, announced today clinical results for the first
and only nitric oxide product, Amplified Maxertion N.O., proven to demonstrate a delay in the onset of neuromuscular fatigue. The key fin...
McCaughey Urges Use of First NYS Hospital Infection Report
NEW YORK, June 30 /PRNewswire-USNewswire/ -- Betsy McCaughey of the Committee to Reduce Infection Deaths (RID) urges families to make use of hospital infection rates made available by the NYS Department of Health today. "Now patients can learn which hospitals in their area have the lowest infecti...
West Wireless Health Institute Teams with Corventis for its First Multicenter, Randomized Clinical Trial
Collaboration will test remote wireless monitoring to prevent hospital readmissions for heart failure
SAN DIEGO, June 24 /PRNewswire-USNewswire/ -- The West Wireless Health Institute (WWHI), one of the world's first
medical research organizations dedicated to advancing health and well-being t...
Roskamp Institute Announces Enrollment of First Students to Participate in its Innovative Research Doctorate Program
Three-Year Neuroscience Research Doctorate Program
SARASOTA, Fla., June 18 /PRNewswire/ -- Sarasota's Roskamp Institute (Roskamp) today announced the first
enrollment of students in its pioneering three-year Ph.D. program through which students will conduct full-time laborator...
Great Basin Scientific, Inc. Raises $3.6 Million in Bridge Funding to Prepare for Launch of First Product
SALT LAKE CITY, June 17 /PRNewswire/ -- Great Basin Scientific, Inc., a privately held life sciences company developing novel, point-of-care molecular diagnostic solutions, today announced it has closed $3.6 million in bridge funding to support the company through 2009 and the launch of its first
HEALTHPOINT-Sponsored Venous Leg Ulcer Clinical Trial Enrolls First Subject for Second Phase II Study
Multi-Center, Randomized Trial to Test Unique Delivery System Using Living Cells to Enhance Wound Healing Marks Milestone for Fort Worth, Texas-based Specialty Biopharmaceutical Company
FORT WORTH, Texas, June 16 /PRNewswire/ -- HEALTHPOINT, Ltd. today announced that it has enrolled the f...
Scottsdale Facility to Be First in U.S. to Showcase True REST Technology
Research Shows Numerous Benefits Including Stress Reduction, Pain Relief and Improved Sleep Patterns
SCOTTSDALE, Ariz., June 16 /PRNewswire/ -- According to the American Medical Association, stress is a factor in more than 75 percent of illness today. The World Health Organization cites stres...
WORLD'S First Robotic Assisted Kidney Transplant Performed at Saint Barnabas Medical Center
LIVINGSTON, N.J., June 4 /PRNewswire/ -- Transplant surgeon, Stuart R. Geffner, M.D., Director of Kidney and Pancreas Transplant Surgery, Saint Barnabas Health Care System Renal and Pancreas Transplant Division, is the first
in the world to use the Intuitive Surgical's da Vinci(TM) Surgical System...
Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer
PLX4032 (R7204) Phase I Results Offer Hope of First
Highly Effective Drug in Melanoma Along With Companion Diagnostic
BASEL, Switzerland, June 1 /PRNewswire/ -- Roche announced today results from a Phase I study with PLX4032 (R7204) a new, highly selective and promising treatment for patients...
Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
- Phase II clinical trial investigating the effectiveness of Intercell's Vaccine Enhancement (VE) Patch in combination with an injectable H5N1 pandemic influenza vaccine started today in the U.S.
- The study is fully funded by HHS - this is the second study conducted under a 5 year USD 128 m ...
Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support
Small Molecule Stem Cell Modulator Administered in Dual Cord Blood Transplant for Hematologic Malignancy
LA JOLLA, Calif., May 27 /PRNewswire/ -- Fate Therapeutics, Inc. announced today that the first
patient has been treated in a Phase 1b clinical trial of FT1050, a small molecule Stem C...
Creighton Medical Laboratories First to Offer New Cancer Test
OMAHA, Neb., May 15 /PRNewswire/ -- Creighton Medical Laboratories, based at Creighton University School of Medicine in Omaha, announced today that it has become the first
clinical laboratory worldwide to offer a new and more effective testing method for cancer.
The method, called SNP arra...
Spherix Reports First Quarter 2009 Earnings
BETHESDA, Md., May 14 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX ), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today reported results for the...
Tris Pharma Announces Acceptance of Its First Two NDAs
ever 24 hour oral liquid sustained release formulation submitted to the FDA
- Validates OralXR(TM) technology platform - eliminates the need to swallow pills by providing sustained release in liquids, chewable tablets, and films
- Upon approval will provide both liquid and tablet...
Quest Diagnostics Introduces First Commercial Laboratory Test for Identifying the H1N1 Swine Flu Virus
Real-time PCR test validated using clinical specimens confirmed
positive for Influenza A H1N1 Swine-origin flu virus
MADISON, N.J., May 11 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX ), the world's leading provider of diagnostic testing, information and service...
BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
BIRMINGHAM, Ala., May 8 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) today announced that, based on discussions with the U.S. Department of Health and Human Services/Biomedical Advanced Research and Development Authority (HHS-BARDA), it is preparing a portion of its i...
Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery
FRIMLEY, England, May 8 /PRNewswire/ --
- Glivec(R) (imatinib) Now Approved in the UK for Post-Surgery Treatment
of Patients With KIT (CD117)-Positive Gastrointestinal Stromal Tumours
(GIST), who are at Significant Risk of the Cancer Returning After Surgery(1)
- Use of Glivec(R) ...
Bionovo Announces First Quarter 2009 Highlights and Financial Results
EMERYVILLE, Calif., May 7 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI ) today announced first
quarter highlights and financial results for the three months ended March 31, 2009.
Bionovo presented data on a preclinical anti-cancer drug candi...
Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
Conference Call Scheduled for Today - Thursday, May 7, 2009 at 5:30 p.m. Eastern Time
MOUNTAIN VIEW, Calif., May 7 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) reported today financial results for the quarter ended March 31, 2009, and provided an update on its prod...
BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
BIRMINGHAM, Ala., May 7 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX ) today announced that an update regarding peramivir and its first
quarter 2009 financial results will be released on Friday, May 8, 2009. Following the release, BioCryst will host a conference call and Web...
Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
- Conference Call Today at 5:00 p.m. Eastern Time -
SOUTH SAN FRANCISCO, Calif., May 5 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today reported financial results for the first
quarter ended March 31, 2009, and ...
Transcept Pharmaceuticals to Report First Quarter 2009 Results
RICHMOND, Calif., May 5 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT ), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced it...
Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study
Largest Study to Date Will Evaluate SilverHawk Plaque Excision System for Treatment of Lower Extremity Peripheral Arterial Disease
PLYMOUTH, Minn., April 30 /PRNewswire/ -- ev3 Inc. (Nasdaq: EVVV ) today announced that the first
patients were recently enrolled in the DEFINITIVE LE post-...
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
Conference Call and Webcast at 11:00 a.m. Eastern Time
THE WOODLANDS, Texas, April 28 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its...
Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin
Unique GeneXpert(R) System Capabilities Enable Powerful New TB Diagnostic Tool
SUNNYVALE, Calif., April 27 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD ) today announced the release of Xpert(R) MTB/RIF as a CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical...
Oakwood Surgeons Perform World's First 3D Surgery Without Special Glasses
Test of prototype 3D display exceeds performance expectations.
LIVONIA, Mich., April 20 /PRNewswire/ -- On Friday, March 20, 2009, in Taylor, Michigan, three Oakwood Heritage Hospital surgeons and their medical support team assembled to perform a series of surgical procedures on a cadaver to ...
Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line
Only 39 Percent of Newly Diagnosed Patients Receive a Drug Within One Year of Their First
Diagnosis, According to a New Report from Decision Resources
WALTHAM, Mass., April 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceut...
PEAK Surgical Announces Completion of First PRECISE Clinical Study, Receipt of Medical Design Excellence Award for PEAK(R) Surgery System and Achievement of Over 1,000 Surgeries Using PEAK PlasmaBlade(TM)
- Company Reports Significant Uptake of PlasmaBlade by U.S. Surgeons Since Product Launch -
PALO ALTO, Calif., April 7 /PRNewswire/ -- PEAK Surgical, Inc., a medical device company that has developed a new tissue dissection system based on a proprietary technology, announced today several mil...
Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203
BETHESDA, Md., April 2 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the filing of the first
clinical trial application (CTA) in Eur...
Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
PRINCETON, N.J., March 31 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) announced today that dosing has started in a phase 1, single ascending dose (SAD) study in healthy volunteers with PSI-7851, a second generation nucleotide analog polymerase inhibitor of hepatitis C virus (HCV)....
Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib
- Afinitor more than doubled time without tumor growth and reduced the risk of disease progression or death by 67% compared with placebo
- Only once-daily oral cancer treatment to directly target mTOR, a protein inside the cell that controls tumor cell division and blood vessel growth
Nation's Laboratory Response Network Marks First Decade of Protecting Public Health
SILVER SPRING, Md., March 30 /PRNewswire-USNewswire/ -- The Laboratory Response Network (LRN), the national laboratory system charged with protecting the public in health emergencies, will mark its first
decade at its national meeting in Orlando, Florida, April 1-3, 2009.
Founded in 1999 by t...
Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development
BOXMEER, Netherlands, March 13 /PRNewswire-FirstCall/ -- Nobilon, the human vaccine business unit of Schering-Plough Corporation (NYSE: SGP ), today announced that it has reached an important milestone with the initiation of its first-in-human clinical development program for SCH 900795, a new...
CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
KING OF PRUSSIA, Pa., March 11 /PRNewswire/ -- CSL Behring has been informed by the U.S. Food and Drug Administration (FDA) that because RiaSTAP(TM) is the first
FDA-approved treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, the company is entitled to seven ye...
Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
ANN ARBOR, Mich., March 9 /PRNewswire/ -- Terumo Heart, Inc. today announced that NewYork-Presbyterian Hospital/ Columbia University Medical Center recently became the second U.S. center, and first
in the Northeast, to implant the DuraHeart(TM) Left-Ventricular Assist System as part of the DuraHe...
IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
Patient Has Mobility Immediately and Makes Rapid Recovery after Procedure Utilizing IlluminOss(TM) Photodynamic Bone Stabilization System
SANTIAGO, Chile, Feb. 24 /PRNewswire/ -- IlluminOss Medical today announced that one of the leading surgeons in Chile, Dr. Sebastian von Unger, has perform...